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ABSTRACT
Analysis of DNA methylation helps to understand the effects of environmental exposures as well
as the role of epigenetics in human health. Illumina, Inc. recently replaced the
HumanMethylation450 BeadChip (450K) with the EPIC BeadChip, which nearly doubles the
measured CpG sites to >850,000. Although the new chip uses the same underlying technology,
it is important to establish if data between the two platforms are comparable within cohorts and
for meta-analyses. DNA methylation was assessed by 450K and EPIC using whole blood from
newborn (n = 109) and 14-year-old (n = 86) participants of the Center for the Health Assessment
of Mothers and Children of Salinas. The overall per-sample correlations were very high (r >0.99),
although many individual CpG sites, especially those with low variance of methylation, had lower
correlations (median r = 0.24). There was also a small subset of CpGs with large mean methylation
β-value differences between platforms, in both the newborn and 14-year datasets. However,
estimates of cell type proportion prediction by 450K and EPIC were highly correlated at both
ages. Finally, differentially methylated positions between boys and girls replicated very well by
both platforms in newborns and older children. These findings are encouraging for application of
combined data from EPIC and 450K platforms for birth cohorts and other population studies.
These data in children corroborate recent comparisons of the two BeadChips in adults and in
cancer cell lines. However, researchers should be cautious when characterizing individual CpG
sites and consider independent methods for validation of significant hits.
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Introduction
Epigenome-wide association studies (EWAS) eluci-
date associations between altered DNA methylation
and health outcomes as well as environmental impacts
on DNA methylation. Until 2016, the most common
method for characterization of DNA methylation in
humans was the Illumina HumanMethylation450
BeadChip (450K), which measured methylation at
~ 450,000CpG sites throughout the genome; however,
Illumina, Inc. has replaced the 450K chip with the
Illumina HumanMethylationEPIC BeadChip (EPIC),
which uses the same technology to measure methyla-
tion at >850,000 CpG sites and covers approximately
90% of the same sites represented on the 450K chip.
The majority of the sites no longer included on the
EPIC chip were sites previously reported to be poor
performing [1].
Many cohorts already have well characterized
methylation data from the 450K chip and, since
the 450K array has been discontinued, any
new genome-wide DNA methylation data will
now, by necessity, come from the EPIC chip.
Consortiums such as Pregnancy and Childhood
Epigenetics (PACE) currently pool 450K data
for large-scale EWAS meta-analyses [2]; how-
ever, many participating cohorts are now
obtaining EPIC data. With the shift to the
EPIC platform, a critical question is whether
individual cohort studies or meta-analyses can
make use of data from both platforms.
Prior studies have examined reliability and
reproducibility of overlapping EPIC and 450K
probes in matched samples of cancer tissue [1,3]
and adult whole blood [4]. Pidsley et al. showed
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that correlation between 450K and EPIC for two of
the same samples of both cancerous and non-can-
cerous cell lines across all overlapping sites was
high (r >0.9) and that reproducibility for identify-
ing differentially methylated positions (DMPs)
between cancer and non-cancerous cells (n = 3
pairs) was excellent, using FDR P <0.01. Kling
et al. also reported high overall correlations
between EPIC and 450K in both fresh-frozen and
formalin-fixed paraffin embedded tumors [3].
Similar results were reported for overall correla-
tion in adult whole blood (n = 145); however, low
correlation was observed for many individual sites
(55% with r <0.2) and were found to correspond
with the variance or range of methylation at a site
[4]. Studies comparing the two platforms in sam-
ples collected from children have not yet been
reported.
This study seeks to examine reproducibility
between EPIC and 450K in umbilical cord blood
and in whole blood of children at age 14. We will
use data from the same DNA samples analyzed on
both the EPIC and 450K chips to explore correla-
tions, difference in performance by type I and II
probes, comparability of estimates for cell-type
proportions, and reproducibility of a DMP analy-
sis between boys and girls. Overall correlations
indicate the correlation between a sample analyzed
by both platforms across all sites [4]. In contrast,
individual site correlations refer to the correlation
of a single site analyzed in all samples on both
platforms.
Results
Study participants
This study included 109 newborns (54.1% girls) and
86 14-year-old subjects (55.8% girls) (Table 1). The
mean age at blood draw for the 14-year-old subjects
was 14.1 (±0.1). There were few preterm births
(7.3% of the newborns, 4.7% among 14-year-old
children), and only one subject with low birth-
weight in both datasets. All subjects were
Mexican-Americans living in the Salinas Valley in
California. The majority (62.8%) of 14-year subjects
were overweight or obese, which is typical for the
Center for the Health Assessment of Mothers and
Children of Salinas (CHAMACOS) cohort [5].
Overall correlation between 450K and EPIC
Replicates ran multiple times on the EPIC plat-
form had very high correlations across all EPIC
probes that passed our filtering quality control
(QC; cord n = 795,592, 14yr n = 795,566). For
four replicates of a newborn sample ran on four
separate chips, the correlation coefficient was
r = 0.998 for each pair of samples. The same was
seen for two sets of 14-year replicates (r = 0.998),
and for a set of Jurkat cell line replicates used as
internal control (r = 0.997).
The correlations for subjects analyzed on
both 450K and EPIC were also high in both
newborn and 14-year participants (Table 2).
For the newborn samples with methylation
measured at 410,741 CpG sites, correlations
ranged from 0.988 to 0.994, with a median of
Table 1. Characteristics of the study population CHAMACOS.
N (%) or mean (±SD)
Newborns
(N = 109)
14-Years
(N = 86)
Child sex
Boys 50 (45.9) 38 (44.2)
Girls 59 (54.1) 48 (55.8)
Child gestational age at birth
≥37 weeks 101 (92.7) 82 (95.3)
34–36 weeks 8 (7.3) 4 (4.7)
Child age at blood draw 14.08 (± 0.06)
Child birthweight
Low birthweight (<2500g) 1 (0.9) 1 (1.2)
Normal birthweight (≥2500g) 108 (99.1) 85 (98.8)
Obesity status at 14 years
Normal (≤85th percentile) 32 (37.2)
Overweight (>85th, <95th
percentile)
17 (19.8)
Obese (≥95th percentile) 37 (43.0)
Table 2. Pearson Correlation coefficients for all EPIC and 450K
comparisons for the population CHAMACOS.
Cord (N = 109,
n = 411,272)
14 year (N = 86,
n = 411,085)
Min Median Max Min Median Max
Samples 0.988 0.993 0.994 0.985 0.994 0.995
CpG sites −0.782 0.235 0.999 −0.877 0.232 0.999
Type I probes −0.782 0.128 0.999 −0.877 0.154 0.999
Type II probes −0.625 0.277 0.999 −0.525 0.270 0.999
Regression
coefficients
0.975 0.976
CD4T 0.993 0.974
CD8T 0.972 0.931
Gran 0.991 0.978
Mono 0.959 0.913
Bcell 0.973 0.961
NK 0.968 0.878
nRBC 0.994
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0.993 (Figure 1). For the 14-year samples mea-
suring methylation at 410,988 CpG sites, corre-
lations were similar, ranging from 0.985 to
0.995 with a median of 0.994.
Correlation and difference at individual CpG sites
In order to compare and combine methylation
values from 450K and EPIC, it is also important
to consider the correlation at each individual CpG
site. These correlations were much lower than
overall sample correlations (Table 2). In newborn
samples, the correlations between the two Illumina
platforms at each CpG site that they have in com-
mon ranged from −0.782 to 0.999, with a median
of 0.235. Samples from 14-year-old showed a simi-
lar distribution of correlations (−0.877 to 0.999,
median = 0.232). In both the newborn and
14-year samples, 71% of CpG sites had a correla-
tion lower than 0.5, while only 10–11% of CpG
sites had a correlation greater than 0.8.
We also examined these correlations separately for
the two types of Infinium chemistry utilized on both
the 450K and EPIC BeadChips. Type II probes had a
better representation of high correlation probes than
type I probes. Figure 2 shows the density of correla-
tions for type I, type II, and type I/II combined in
newborn samples with a shift toward a higher density
of strong correlations in type II probes. The median
correlation for type I probes was 0.128 while type II
probes had a median correlation of 0.277. Similar
results were seen for type I and II probes in 14-year
samples (Table 2). In cord samples, correlations were
stronger at CpG sites with higher variance of
Figure 1. β values for all overlapping probes on 450K vs. beta values on EPIC for a newborn sample.
Figure 2. Distribution of correlation coefficients for individual CpG sites, separated by probe type. Type II probes have a greater
density of CpG sites with higher correlation coefficients.
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methylation between subjects, whereas correlations
were weaker at CpG sites with low methylation var-
iance (Figure 3(a)). Sites in the lowest quartile of
correlation (including all sites with negative correla-
tion) had amedian variance of 5e-5withmeanmethy-
lation at those sites very close to 0 or 1 (Figure 3(b)),
while sites in the highest quartile of correlation had a
median variance of 0.001 with a much broader range
of methylation values among the subjects (Figure 3
(c)). Similar results were seen in 14-year samples.
Paired t-tests showed substantial β value differ-
ences between 450K and EPIC measures for a
small fraction of CpG sites. In the newborn sam-
ples, 1,416 (0.003%) sites had a mean β difference
greater than 0.25 while 62 sites had a mean β
difference greater than 0.5 (Figure 4). Similarly,
in 14-year samples, 1,062 (0.004%) sites had a
mean β difference greater than 0.25, while 38
sites had a mean β difference greater than 0.5.
There was considerable overlap between CpG
sites with large β differences in the cord and 14-
year datasets, meaning there were consistent dif-
ferences in β between the two Illumina platforms
in both datasets for many of the CpG sites. Of the
38 CpG sites with a β difference greater than 0.5 at
14 years, 31 were included in the 62 CpG sites
significant in cords. Of the 1,062 sites with β
difference greater than 0.25 at 14 years, 942 were
Figure 3. The correlation of β values between 450K and EPIC relative to the variance of methylation at each site (top). Sites in the
lowest quartile of correlation had low variance and were mostly completely methylated or completely unmethylated (bottom left).
Sites in the highest quartile of correlation had high variance of methylation (bottom right).
Figure 4. The absolute difference in β value at each CpG site between 450K and EPIC for newborns is plotted on the y-axis. Sites
which also showed large differences >0.25 in the 14-year data set are highlighted in green and counts of sites exceeding thresholds
of 0.1, 0.25, and 0.5 are shown on the right side of the plot.
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included in the 1,416 CpG sites significant in
cords. All sites with an average β difference greater
than 0.25 had an FDR adjusted P value lower than
0.05. This subset of CpGs had a similar distribu-
tion of probe type and distance from genes as the
overall BeadChip. Further investigation of these
sites did not identify specific biological pathways
either. The CpG sites with the largest mean β
differences (>0.5) in both cord and 14-year data-
sets were not low variance sites.
Cell type predictions estimated by two platforms
Many methylation studies adjust for cell type het-
erogeneity using the estimateCellCounts function
in the R package minfi [6]. Cell type predictions
for seven cell types in newborns, estimated using a
cord blood reference data set, were highly corre-
lated for samples run on 450K and EPIC (r = 0.96
to 0.99). For 14-year samples the six cell types
estimated using an adult reference dataset also
showed high correlations; however they were
slightly lower than newborn cell composition esti-
mates (r = 0.88 to 0.98) (Table 2). Individual site
correlations between the two platforms for the
subset of 600 to 700 CpG sites used for cell type
prediction in children were higher than average
for the other sites on the BeadChips with a median
r = 0.73 and small mean differences between the
platforms. These sites also had higher variance of
methylation.
Replication of DNA methylation sex differences
We previously reported on site-specific differential
DNA methylation between boys and girls in the
CHAMACOS cohort [7]. Here, we used a similar
analysis in order to assess the reproducibility
between EPIC and 450K in EWAS studies by run-
ning the same regression analyses to identify auto-
somal DMPs between boys and girls using both
450K and EPIC methylation values as the out-
come, adjusting for cell type heterogeneity. There
was high correlation of the regression coefficients
from each model in both newborn (r = 0.975) and
14-year analyses (r = 0.976) (Figure 5). Of the
16,368 significant CpG sites differentially methy-
lated by sex in 450K, 80% (n = 13,134) were also
found significant in EPIC analyses. Of the top
1,000 450K hits, 999 (99%) were significant EPIC
hits in regard to sex differences in DNA methyla-
tion (Figure 6).
Discussion
Comparisons of DNA methylation at birth and
adolescence by both 450K and EPIC BeadChips
show that the overall methylation patterns
between 450K and EPIC are highly correlated;
however, individual sites have a broad range
including some low and even negative correla-
tions. We found type II probes to have higher
individual site correlations than type I probes
between the platforms and also report a relatively
Figure 5. Regression β values for all overlapping probes on 450K vs. regression beta values on EPIC analyses of differentially
methylation positions by sex in newborns.
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small subset of CpG sites with consistently large
β value differences. We also saw high correlation
of cell type proportion estimates and strong
replication of DMPs between boys and girls in
both datasets. Since all samples from both data-
sets in our CHAMACOS study were isolated
from whole blood, the results of this comparison
are primarily informative to other studies analyz-
ing DNA methylation in blood. This is one of
the most frequently used sample type for epige-
netic population studies of children and
adults [8].
Results for overall correlations in children cor-
roborate studies in adult blood [4] and cancer
tissue [1], which show overall correlation coeffi-
cients greater than 0.9. Also, similar to the study in
adult blood, individual site correlations were much
lower in the newborns and children in our study.
We also observed that CpG sites with lower var-
iance of methylation values had weaker correla-
tions. Sites with small variance showed that nearly
all subjects were completely unmethylated (β = 0)
or completely methylated (β = 1). Sites with low
variance and extreme methylation values are likely
more sensitive to small differences between the
two platforms. Weak correlation could mean that
methylation measurements are unreliable and
could have difficulty replicating at those sites.
Our results of a practical application in a cohort
study exploring DMPs related to sex shows the
majority of hits replicate very well by the two
platforms in the newborn and 14-year-old
datasets.
The majority of new probes on the EPIC chip
are type II – EPIC consists of 84% type II probes,
while 450K contains 72% type II probes. Even after
quantile normalization, which aims to adjust for
differences in Infinium chemistry at type I vs. type
II probes, we see that type II probes have a higher
distribution of strong correlations between the two
platforms. Interestingly, a study in adult blood
reported very similar results for the two probe
types [4]. These differences underscore the impor-
tance of including a normalization technique for
probe type in the methylation data processing
pipeline.
We observed a subset of sites with large β value
differences by 450K and EPIC that overlap in the
newborn and 14-year datasets. We analyzed these
sites for specific characteristics that may differ
from better performing sites. We first looked for
enrichment of location in CpG islands, shores, and
shelfs, and saw similar distributions to the overall
chip. Proportions of type I and type II probes also
did not differ from the rest of the probes.
Additionally, a pathway analysis revealed that no
specific genes or biological processes were
enriched in the problematic probes. Overall, these
probes with large β value differences between the
450K and EPIC chip were spread throughout the
epigenome without any identifying characteristics.
These CpG sites showed significantly lower corre-
lations than the median of all sites, showing that
this finding is not explained by a shift in mean β
values between the platforms. The same CpG sites
with large differences in β values were not
observed between replicate samples analyzed on
either 450K or EPIC, suggesting this difference is
likely due to the variation between the two plat-
forms. Unlike many of the CpG sites with lower
Figure 6. Manhattan plot showing differentially methylation positions by sex in newborns on 450K in autosomes. Sites highlighted
in green are the 999 of the top 1,000 autosomal 450K hits, which were significant (FDR q <0.05) in EPIC analyses.
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correlations between 450K and EPIC, these sites
did not show significantly lower variance in
methylation values, suggesting that these probes
may be poor performing. This subset of CpG
sites could be unreliable for comparison when
combining EPIC and 450K datasets. Researchers
may consider filtering these sites and/or validation
by an alternative methodology, particularly when
conducting an analysis that includes data from
both platforms (Table S1).
We were also able to assess the performance of
minfi’s implementation of a cord blood reference
data set as well as an adult reference dataset and
found that estimates for cell type proportions in
each subject were very similar whether using 450K
or EPIC data. Currently, the cell-sorted reference
methylation datasets for both cord and adult blood
are limited to 450K data; therefore, only overlap-
ping probes were used for cell proportion esti-
mates in our analysis. The high correlation
estimates for both platforms mean that the subset
of CpG sites used for these blood cell composition
estimations perform comparably on the two
BeadChips. Additionally, we noted that the med-
ian correlations for the subset of probes used to
estimate cell type proportions are higher than the
median correlations for overall probes. This stabi-
lity is encouraging for studies that use this popular
reference method to adjust for cell type heteroge-
neity in their epigenetic analyses.
A prior study in the CHAMACOS cohort
reported over 3,000 CpG sites in autosomes to be
differentially methylated between newborn boys
and girls [7]. To assess reproducibility of DMP
analyses between the two platforms, we performed
a similar analysis using the newborns and 14- year
subjects with data on both the 450K and EPIC
chips. Results from running the same analysis
using either 450K or EPIC data with their respec-
tive estimated cell-count adjustments produced
very similar results of differential DNA methyla-
tion by sex at both ages. The majority of signifi-
cant hits replicate by the two platforms, and the
effect sizes for differential methylation are highly
correlated across all sites. We saw that the median
correlation for sites that replicated (r = 0.89) was
higher than sites that did not replicate (r = 0.53).
This shows that sites with lower correlation may
be less reliable by at least one of the platforms.
Similar replication between 450K and EPIC for
DMP analyses was reported in cancer cell lines
[1] and in adult age differences [4]. Ongoing ana-
lyses with the PACE consortium will further inves-
tigate sex-related DNA methylation differences as
well as the combination of data from the 450K and
EPIC BeadChips in meta-analyses of multiple
participating cohorts.
We suggest that future studies incorporating
data from one or both BeadChips conduct sensi-
tivity analyses filtering sites with large differences,
lower correlation, or lower variance, and/or vali-
date hits with an alternative method, such as tar-
geted pyrosequencing [8]. Since CpG sites with
low variability or at the extreme ends of methyla-
tion distribution could still be biologically infor-
mative to certain studies, sensitivity analyses may
be more appropriate rather than strict filtering
based on variability or correlation between plat-
forms. In general, we anticipate the EPIC chip to
be more reliable than the 450K chip. The new
EPIC chip contains 90% of the probes on 450K,
and many of the 10% no longer included on the
EPIC chip were previously identified as underper-
forming. Additionally, in our analyses we saw
slightly better performance of type II probes, and
the majority of new probes added to the EPIC chip
make use of the type II Infinium chemistry.
Although we found that individual site correla-
tions are relatively low, these new data add to
previous studies that have shown that the EPIC
and 450K chips behave similarly in the practical
use of DMP analyses. Now, we also show that the
performance between EPIC and 450K is consistent
between whole blood of both newborns and
children.
Methods
Study participants
Subjects were participants in the CHAMACOS
longitudinal birth cohort study examining the
impact of pesticide and other environmental expo-
sures on the health and development of Mexican-
American children living in the Salinas Valley, an
agricultural region in California. A detailed
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description of the CHAMACOS cohort has pre-
viously been published [9]. A total of 601 women
were enrolled during pregnancy and 526 were fol-
lowed to delivery of a liveborn singleton infant. For
this study, we included subjects that had methyla-
tion data on both the 450K and EPIC platforms
measured in cord and blood from the children at
14 years. This included 109 newborns (cord blood)
and 86 14-year-old subjects (M
± SD = 14.1 ± 0.1 years old) with sufficient DNA
for these analyses.
Blood collection and processing
Cord blood specimens were collected by hospital
staff at time of delivery and 14 year blood was
collected by venipuncture by a phlebotomist at
the CHAMACOS field office. After separation
into clots, serum, and buffy coats, they were stored
at −80°C until analysis. DNA was isolated from the
banked non-heparinized umbilical cord and 14-
year blood clot samples using QIAamp DNA
Blood Maxi Kits (Qiagen, Valencia, CA) according
to the manufacturer’s protocol with minor mod-
ifications, as previously described [10].
EPIC and 450K BeadChip methylation analysis
DNA aliquots of 1 µg were bisulfite converted using
Zymo Bisulfite Conversion Kits (Zymo Research,
Orange, CA). DNA was whole-genome amplified,
enzymatically fragmented, purified, and applied to
the Illumina Infinium HumanMethylation450
BeadChips (Illumina, San Diego, CA) according to
the Illumina methylation protocol [11,12]. Both
EPIC and 450K chips were analyzed using the
Illumina Hi-Scan system. DNA methylation was
measured at 485,512 CpG sites on the 450K
BeadChip and 866,836 CpG sites on the EPIC
BeadChip. QC measures were previously described
[13] and included use of repeats and randomization
of samples across chips and plates. The same QC
was applied for EPIC analyses.
DNA methylation data processing
DNA methylation data was processed using the R
package minfi [6]. Raw intensity data (IDAT) files
for both 450K and EPIC data were loaded and
combined into an array including only overlap-
ping CpG sites and subjects with DNA analyzed
on both platforms. Cord and 14-year samples were
processed separately. Prior to probe filtering, there
were 452,567 overlapping probes. We then
checked for samples where <95% of probes had a
detection P value <0.01. All samples passed this
quality control. We then subtracted background
signal and corrected for dye bias using ‘noob’
normalization (preprocessNoob) and normalized
for differences between type I and type II probes
using quantile normalization (preprocessQuantile).
Before conducting any correlation analyses, we
confirmed samples were from the same subject
on each platform by comparing β values at the
59 overlapping SNPs included on the 450K and
EPIC chip.
Sites with annotated probe SNPs (n = 59), and
with common SNPs identified in the MXL
(Mexican ancestry in Los Angeles, California)
HapMap population (n = 13,754) [14] were
excluded. Cross-reactive probes have been pre-
viously identified [15] and were removed according
to Chen et al. (n = 27,167) [16]. Probes where 95%
of samples had detection P values >0.01 were also
dropped (cord n = 834; 14yr n = 561). Finally, we
removed probes which Illumina identified as
underperforming leaving 410,741 CpGs for analysis
in cord samples and 410,988 CpGs for analysis in
14-year samples.
Cell type proportions were also estimated using
minfi [6] (estimateCellCounts). For cord samples,
this function predicts proportions of seven cell
types in relation to a cord reference data set that
includes nucleated red blood cell counts [17],
while for 14 year samples, this function uses the
Reinius adult reference data set to estimate pro-
portions of six cell types [18].
Statistical analyses
In order to assess overall reproducibility, we calcu-
lated the Pearson correlation coefficient for each
subject across all probes to obtain an overall correla-
tion per subject on both platforms. In addition to
looking at correlation across all sites, we assessed
correlation separately by type I and type II probes.
We also calculated correlation coefficients as well as
variance of β-methylation per probe, meaning a
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single probe across all subjects, to assess compar-
ability of an individual methylation value. Finally,
we calculated correlations between the estimated cell
type proportions from each platform. In order to
determine the average difference in β value pro-
duced by 450K and EPIC, we subtracted the mean
β for all subjects at each probe on EPIC from the
mean β for all subjects at each probe on 450K and
conducted paired t-tests to check for statistical sig-
nificance. We also conducted a pathway analysis to
determine if the sites with large differences between
the two platforms are enriched for any biological
pathways [19].
Assessment of the reproducibility of interro-
gating differentially methylated positions
(DMPs) was performed by fitting a limma [20]
linear model with empirical Bayes variance
shrinkage using either 450K or EPIC methyla-
tion as the outcome and sex as the predictor.
Analyses also adjusted for cell type proportions.
All statistical analyses were conducted using R
version 3.4.1 [21].
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